The Specialised Services Commissioning Innovation Fund (SSCIF) aims to rapidly evaluate innovative models of care, pathways, technologies and medicines to generate evidence on quality, cost and impact for NHS specialised services. The SSCIF will fund evaluation projects jointly with manufacturers to fill data gaps preventing national commissioning decisions. Successful projects could result in widespread adoption across the NHS and discounted national procurement agreements, presenting an unrivalled opportunity for partnership and adoption of transformative innovations.

1. Benefits of engaging with the
Specialised Services
Commissioning Innovation
Fund (SSCIF)
Andrew Jones, Senior Medical Science Manager| Bristol-Myers Squibb
Bernie Stocks, Associate Director, Innovation Adoption, Specialised Services |
NHS England

2. Specialised Services Innovation
Bernie Stocks
13 June 2013

3. Specialised Services Innovation ‘job card’
3
IHW:
Create an
innovation
fund
Legal Duty to
promote
research and
innovation
NHS
England
Ambition:
equity&
excellence-
specialised
care
The
Mandate
The Carter
Review
http://www.dh.gov.uk/pro
d_consum_dh/groups/dh
_digitalassets/document
s/digitalasset/dh_131784
.pdf
http://www.dh.gov.uk/prod_consu
m_dh/groups/dh_digitalassets/@
dh/@en/documents/digitalasset/d
h_4135216.pdf
http://mandate.dh.gov.uk/
NHS | ABPI | 13 04 13

4. 4
Specialised Services
Commissioning Innovation
Fund (SSCIF)

5. SSCIF
For innovations:
Which are new to NHS specialised services or applied in a way that is new
to NHS specialised services
That have shown promise of delivering an improvement in the quality or
cost and affordability of service delivery
Which have a clearly defined value proposition and, if a service or product,
have reached entry levels of safety ready for evaluation in clinical practice.
SSCIF Evaluation Projects
Will be rapid, typically ranging from six to 18 months
Can involve collaboration between commissioners, clinicians, patients,
innovators and the commercial sector
5

6. SSCIF – Prime Objective
• To generate missing data and information on the impact of the innovation on:
 Quality,
 Cost and affordability and
 NHS activity levels
…which can be used to inform commissioning policy
• By rapidly evaluation in a clinical, healthcare service setting, innovative
models of care, pathways, approaches, devices, technologies, products and
medicines with the potential to deliver high impact change for NHS
specialised services
6

7. • Idea
• Design
• Prototype
Invention
• Safety Testing
• Effectiveness Evaluation
• Effectiveness Testing
• Innovation Implementation
• Early Implementation
• Procurement
• Secondary Implementation
Adoption
• Voluntary Diffusion
• Advisory Diffusion
• Mandatory Diffusion
Diffusion
Focus
of
SSCIF
SSCIF Focus within the stages of Innovation

8. SSCIF will test innovations at these stages:
• Proof of ConceptEffectiveness
Evaluation
• Proof of Impact
Effectiveness
Testing
• Post launch evaluation
Innovation
Implementation
• Early adopter
implementation
Early
Implementation
Adoption

9. SSCIF - Benefits
• Creation of an evidence base for use in national commissioning decisions
which will result in rapid, widespread adoption of proven innovations in the
NHS.
• Earlier access to innovative care for patients.
• Increased value for money to the NHS.
• Increase knowledge of offer and impact of individual innovations/products
9

10. Process
decision
Simple on-line Step 1: Self-Assessment
Step 3: Detailed Submission (Table top expert review
Step 2: Qualifying Submission Form (CRG Chair reviews)

11. Process
• Open to healthcare staff, manufacturers, clinicians, researchers, patient
groups and commissioners.
• Submissions can be made anyone at Steps 1 and 2, but by Step 3, a
practising Lead Healthcare Practitioner employed by a healthcare
organisation that supports the generation of wealth in the UK will need to
sponsor and agree to lead the project.
• Manufacturers and others can form alliances with health staff to do this.
Medical Directors of the Healthcare Lead’s organisation will need to endorse
the submission.

12. Funded Projects - documents and requirements
decisionFunded SSCIF Evaluation Projects will have a Service Level Agreement
with a contract schedule taken from the Step 3: Detailed Submission
Form detailing the key activities, key milestones, intended outcomes and
key performance indicators.
Lead Applicants will be provided with sample templates for:
 A project initiation document
 A protocol for local ethical approval
 Informed Consent and patient participation
 Data set for Patient Information Leaflets
 Headings for final report including final products, factors for success
etc.

13. SSCIF Next Steps

14. Innovation Health and Wealth
• UK Plan for Growth March 2011
– Challenged NHS CE to review adoption and diffusion of
innovation
• Prompted the NHS CE Review
– Asked major stakeholders what might be done to
accelerate the spread of innovations in the NHS
– Consultation across NHS, Government, Industry,
Academia and Patient Groups
– 310 responses received; 28% from industry (Incl Med Tech)
– 17% of respondents identified the need for innovation
funds (including a specific fund for Specialised Services)
• Resulted in IHW (Dec 2011)
– 31 Actions to drive the adoption and diffusion of innovation

15. Reason for the SSCIF
• Many innovations with promise available to the NHS
– But often languishing at a local/regional level
– No widespread uptake due to lack of commissioning
evidence
• Evidence Generation in Specialised Services often
difficult
– Low volume
– Hard to achieve levels of evidence similar to those
generated by RCTs
– Even data (incl. RCTs) sufficient for MA are often not
enough to convince commissioners of the innovation’s
value in clinical practice

16. Ethos of the SSCIF
• Aid accelerated adoption and diffusion of transformational
innovations
– Generate evidence on the value of promising innovations
that are available for use in the NHS
– To enable evidence based commissioning decisions to be made
– Make use of New Structure
– National commissioning decisions for specialised services
– Set a paradigm for adoption and diffusion of innovation in a
clinically led fashion

17. Another Hurdle?
• No!!
• In the past
– Drugs not considered by NICE or not recommended due to
lack of evidence
– Commissioning considered independently by 10 SCGs
– Each following a different process (rarely evidence generating)
– Potential for 10 different decisions
• Now
– 1 National decision on specialised services commissioning
– Must be based on robust evidence
– How can this be obtained if not a NICE topic or not recommended
due to lack of evidence
• The SSCIF is a real opportunity

18. Silo Busting
• SSCIF Evaluation Projects will:
– Look at complete patient pathway, taking into account:
– Impact of the innovation on outcomes; and
– Cost and efficiency; and
– Activity levels
across all parts of the pathway
– Consider:
– Societal Impacts
– Gaps in service provision (degree of unmet need)
– Generate evidence to fill data gaps that are preventing
commissioning
– Data gaps on effectiveness and costs in the NHS

19. Real Opportunity for Partnership
• The SSCIF aims to generate evidence that is:
– Is needed by NHS England for national commissioning decisions
in the new structure
– Could benefit the manufacturer once generated
• Therefore generation of evidence should be funded jointly
– NHS England has set up a fund (SSCIF) to generate the
information it needs for all innovations
– Manufacturers should not rely wholly on NHS funding to generate
data on their products (State Aid)
– So for commercial applications to the SSCIF, the evaluation
projects will need to be jointly funded by the applicant and by the
SSCIF

20. Unrivalled potential
• A successful evaluation project will result in
– National Commissioning Policy
– potentially a National commissioning decision.
– This is unlike anything seen before in specialised services
• The partnership ethos will extend to commissioning
arrangements post SSCIF evaluation
– Exclusivity terms
– Discounted purchase price